



## IBA to Launch New Customer CAREprogram during EANM Annual Meeting

**IBA's CAREprogram provides cost efficient and customer-tailored solutions to boost uptime and maximize ROI of radiopharmaceuticals production centers**

**Louvain-la-Neuve, Belgium, October 26, 2012** - IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, will present IBA's new customer CAREprogram during the 2012 European Association of Nuclear Medicine (EANM) annual meeting on October 28th in Milan, Italy.

The CAREprogram provides continuous support in furthering skills and applications, boosting the uptime and maximizing the return on investment of radiopharmaceuticals production centers with all the latest innovations, services and training.

The CAREprogram includes a complete portfolio of solutions to install, optimize, support and maintain its equipment. Given the rapid pace technology evolves, IBA has also developed both upgrade packages tailored to its customer's specific configurations and training programs to increase accelerator performance and operator efficiency.

"At IBA, we are proud of our ability to support our customers throughout the whole life cycle of their equipment. Increasingly complex radiopharmaceuticals production centers demand an increased level of service to maximize their efficiency," said **Bruno Scutnaire, Head of IBA RadioPharma Solutions**. "IBA is a world leader in radiopharmaceuticals and is strongly committed to improving our customers' productivity and efficiency and with the IBA CAREprogram, we provide reliability which ultimately leads to lower overall operating costs."

The CAREprogram will be presented on IBA booth #504 during the whole EANM'12 congress.

### **About IBA RadioPharma Solutions**

Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers.

### **About IBA**

IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The company's expertise lies in the development of next-generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully-integrated IntegraLab® system.

Headquartered in Belgium and employing more than 1200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors and provides high quality services and products for oncology specialists and cancer patients.



## Press release |

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

**For further information please contact:**

**IBA RadioPharma Solutions**

Thomas Ralet  
Vice-President Marketing  
+32 10 475 890  
[thomas.ralet@iba-group.com](mailto:thomas.ralet@iba-group.com)

**For media and investor enquiries:**

**M:Communications**

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson  
+44 (0) 207 920 2333  
[IBA@mcomgroup.com](mailto:IBA@mcomgroup.com)